Huai'an First People's Hospital
🇨🇳China
Clinical Trials
8
Active:0
Completed:1
Trial Phases
2 Phases
Phase 2:4
Not Applicable:4
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
Not Applicable
4 (50.0%)Phase 2
4 (50.0%)A Single-center, Single-arm, Phase II Clinical Study of Iparomlimab and Tuvonralimab Injection Combined With Regorafenib in the Treatment of Advanced Second-line or Above Hepatocellular Carcinoma
Not Applicable
Not yet recruiting
- Conditions
- Hepatocellular Carcinoma (HCC)
- Interventions
- Drug: Iparomlimab and Tuvonralimab Injection (QL1706) in combination with Regorafenib
- First Posted Date
- 2025-08-11
- Last Posted Date
- 2025-08-11
- Lead Sponsor
- Huai'an First People's Hospital
- Target Recruit Count
- 24
- Registration Number
- NCT07115550
A Prospective, Single Arm, Open Label, Phase II Clinical Study on the Efficacy and Safety of Ivonescimab (AK112) Combined With TAS-102 in the Treatment of Refractory MSS/pMMR Advanced Colorectal Cancer
Not Applicable
- Conditions
- MSS/pMMR Type Metastatic Colorectal Adenocarcinoma Patients
- Interventions
- Drug: Ivonescimab,TAS-102
- First Posted Date
- 2025-04-20
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- Huai'an First People's Hospital
- Target Recruit Count
- 35
- Registration Number
- NCT06936488
- Locations
- 🇨🇳
The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University#Huai'an First People's Hospital#, Huai'an,, Jiangsu, China
Oxygen Study-Orelabrutinib Combined With Obinutuzumab(O2) for First-Line Treatment of Marginal Zone Lymphoma
- First Posted Date
- 2024-08-22
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Huai'an First People's Hospital
- Target Recruit Count
- 51
- Registration Number
- NCT06566807
- Locations
- 🇨🇳
The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University#Huai'an First People's Hospital#, Huai'an,, Jiangsu, China
A Clinical Study Evaluating the Safety and Efficacy of ZRMT Regimen in the Treatment of PCNSL
Not Applicable
Recruiting
- Conditions
- Primary Central Nervous System Lymphoma
- Interventions
- First Posted Date
- 2024-06-06
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- Huai'an First People's Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT06445257
- Locations
- 🇨🇳
The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University（Huai'an First People's Hospital）, Huai'an, Jiangsu, China
Clinical Study Protocol for the Treatment of ND-AML and RR-AML With KMT2A Gene Abnormalities Using VHEA.
Not Applicable
Recruiting
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2024-03-25
- Last Posted Date
- 2024-03-25
- Lead Sponsor
- Huai'an First People's Hospital
- Target Recruit Count
- 34
- Registration Number
- NCT06328179
- Locations
- 🇨🇳
The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University（Huai'an First People's Hospital）, Huai'an, Jiangsu, China
- Prev
- 1
- 2
- Next
News
No news found